Related Experiment Video

Updated: Jun 17, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for

David S Geller1, Richard Gorlick

  • 1Montefiore Medical Center, Department of Orthopaedic Surgery, 3400 Bainbridge Avenue, Bronx, NY 10467, USA. dgeller@montefiore.org

Expert Opinion on Pharmacotherapy
|December 17, 2009
PubMed
Abstract

Insights

Targeted therapy for HER-2 positive osteosarcoma shows promise but requires further research. Current methods for assessing HER-2 expression and treatment effectiveness are not yet established, highlighting the need for new approaches.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Chemotherapy has limited success for metastatic or refractory osteosarcoma.
  • New therapeutic strategies, including targeted therapy, are needed.
  • Trastuzumab (Herceptin) is being explored for HER-2 positive osteosarcoma.

Purpose of the Study:

  • To review the literature on HER-2 expression in osteosarcoma.
  • To assess the prognostic relevance of HER-2 in osteosarcoma.
  • To evaluate the potential of HER-2 targeted therapy.

Main Methods:

  • Systematic review of studies from 1996 to present.
  • Focus on HER-2 expression and its prognostic significance.
  • Analysis of HER-2 directed therapy effectiveness.

Main Results:

  • HER-2 expression's prognostic value in osteosarcoma is controversial.
  • Standardized methods for assessing HER-2 expression are lacking.
  • The effectiveness of HER-2 targeted therapy is not yet established.

Conclusions:

  • Osteosarcoma is a rare cancer, making large prospective studies challenging.
  • Defining specific therapies for rare cancer subpopulations requires further investigation.
  • The feasibility of targeted therapy for HER-2 positive osteosarcoma needs more research.

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...